ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter and year ended December 31, 2025 after market close on March 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ImmuCell (Nasdaq: ICCC) will report unaudited financial results for the quarter and year ended December 31, 2025 after market close on March 4, 2026. The company will host a conference call on March 5, 2026 at 9:00 AM ET to review results.
Dial-in numbers, replay access (code #2017737) available through March 12, 2026. ImmuCell expects no change to preliminary sales disclosed January 8, 2026 and plans to file its Form 10-K on or before March 31, 2026.
Details
News Market Reaction – ICCC
On Feb 18, the day this news came out, ICCC closed 3.85% above the previous close.
Data tracked by StockTitan Argus for the Feb 18 session.
Key Figures
- Results release date
- March 4, 2026
- Unaudited Q4 and FY 2025 results after market close
- Earnings call time
- 9:00 AM ET
- Conference call on March 5, 2026
- Replay end date
- March 12, 2026
- Teleconference replay availability
- Replay access code
- 2017737
- Conference call replay code
- Form 10-K filing deadline
- On or before March 31, 2026
- Expected filing of Annual Report on Form 10-K
Previous Earnings date Reports
-
Announced Q3 2025 results release date and conference call logistics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
form 10-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ET
PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026.
The Company is planning to host a conference call the next morning, Thursday, March 5, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties can access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international) at 9:00 AM ET. A teleconference replay of the call will be available until March 12, 2026 at (855) 669-9658 (toll free) or (412) 317-0088 (international), utilizing replay access code #2017737.
The Company anticipates no change to the preliminary sales results for the quarter and year ended December 31, 2025 that were disclosed on January 8, 2026. The Company expects to file its Annual Report on Form 10-K on or before Tuesday, March 31, 2026.
About ImmuCell:
ImmuCell Corporation's (Nasdaq: ICCC) purpose is to create scientifically proven and practical products that improve cattle health and productivity. ImmuCell manufactures and markets First Defense®, providing Immediate Immunity™ to newborn dairy and beef calves. Press releases and other information about the Company are available at: http://www.immucell.com.
| Contacts: | Olivier te Boekhorst, President and CEO |
| Timothy C. Fiori, Chief Financial Officer | |
| ImmuCell Corporation | |
| investor.relations@immucell.com | |
| Joe Diaz, Robert Blum and Joe Dorame | |
| Lytham Partners, LLC | |
| iccc@lythampartners.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.